| Name | 
              Number of Publications
             | 
              Most Recent Publication
             | 
              Publications by All Authors
             | 
              Concept Score
             | 
              Why?
             | 
|---|
| Drug Delivery Systems | 84  | 2024  | 252  | 6.880  | 
                  Why?
                 | 
| Polymers | 45  | 2024  | 133  | 3.780  | 
                  Why?
                 | 
| Tissue Engineering | 19  | 2023  | 52  | 3.370  | 
                  Why?
                 | 
| Biocompatible Materials | 24  | 2023  | 60  | 3.020  | 
                  Why?
                 | 
| Nanoparticles | 26  | 2024  | 104  | 2.820  | 
                  Why?
                 | 
| Chitosan | 20  | 2023  | 46  | 2.550  | 
                  Why?
                 | 
| Tissue Scaffolds | 17  | 2023  | 45  | 2.470  | 
                  Why?
                 | 
| Animals | 76  | 2024  | 1081  | 2.320  | 
                  Why?
                 | 
| Drug Carriers | 29  | 2024  | 93  | 2.280  | 
                  Why?
                 | 
| Nanostructures | 9  | 2021  | 40  | 1.570  | 
                  Why?
                 | 
| Hydrogel, Polyethylene Glycol Dimethacrylate | 8  | 2018  | 17  | 1.420  | 
                  Why?
                 | 
| Nanomedicine | 7  | 2021  | 24  | 1.400  | 
                  Why?
                 | 
| Delayed-Action Preparations | 21  | 2019  | 68  | 1.340  | 
                  Why?
                 | 
| Hydrogels | 15  | 2022  | 42  | 1.330  | 
                  Why?
                 | 
| Wound Healing | 9  | 2025  | 29  | 1.280  | 
                  Why?
                 | 
| Humans | 95  | 2025  | 14537  | 1.260  | 
                  Why?
                 | 
| Chitin | 3  | 2013  | 3  | 1.180  | 
                  Why?
                 | 
| Curcumin | 4  | 2020  | 13  | 1.080  | 
                  Why?
                 | 
| Pharmaceutical Preparations | 12  | 2024  | 44  | 1.060  | 
                  Why?
                 | 
| Polyethylene Glycols | 14  | 2021  | 49  | 0.990  | 
                  Why?
                 | 
| Models, Molecular | 13  | 2018  | 84  | 0.970  | 
                  Why?
                 | 
| Chemistry, Pharmaceutical | 26  | 2017  | 76  | 0.970  | 
                  Why?
                 | 
| Nerve Regeneration | 7  | 2021  | 22  | 0.960  | 
                  Why?
                 | 
| Regenerative Medicine | 4  | 2025  | 12  | 0.950  | 
                  Why?
                 | 
| Tablets | 12  | 2019  | 39  | 0.900  | 
                  Why?
                 | 
| Peptides | 5  | 2020  | 40  | 0.890  | 
                  Why?
                 | 
| Pectins | 7  | 2016  | 14  | 0.880  | 
                  Why?
                 | 
| Drug Liberation | 23  | 2019  | 52  | 0.870  | 
                  Why?
                 | 
| Ovarian Neoplasms | 6  | 2020  | 15  | 0.870  | 
                  Why?
                 | 
| Spinal Cord Injuries | 2  | 2014  | 18  | 0.860  | 
                  Why?
                 | 
| Zinc Oxide | 2  | 2012  | 2  | 0.800  | 
                  Why?
                 | 
| Spectroscopy, Fourier Transform Infrared | 18  | 2018  | 44  | 0.790  | 
                  Why?
                 | 
| Acrylic Resins | 6  | 2017  | 17  | 0.770  | 
                  Why?
                 | 
| Anti-Bacterial Agents | 6  | 2016  | 293  | 0.750  | 
                  Why?
                 | 
| Administration, Oral | 20  | 2021  | 127  | 0.740  | 
                  Why?
                 | 
| Bandages | 6  | 2022  | 21  | 0.710  | 
                  Why?
                 | 
| Hydrogen-Ion Concentration | 20  | 2024  | 63  | 0.710  | 
                  Why?
                 | 
| Polymethacrylic Acids | 6  | 2024  | 14  | 0.690  | 
                  Why?
                 | 
| Antineoplastic Agents | 8  | 2019  | 62  | 0.660  | 
                  Why?
                 | 
| Alginates | 10  | 2024  | 34  | 0.650  | 
                  Why?
                 | 
| Nanofibers | 5  | 2022  | 13  | 0.640  | 
                  Why?
                 | 
| Printing, Three-Dimensional | 8  | 2023  | 21  | 0.640  | 
                  Why?
                 | 
| Particle Size | 19  | 2022  | 73  | 0.620  | 
                  Why?
                 | 
| Proteins | 6  | 2021  | 20  | 0.610  | 
                  Why?
                 | 
| Anti-HIV Agents | 8  | 2019  | 1324  | 0.610  | 
                  Why?
                 | 
| Polysaccharides, Bacterial | 5  | 2021  | 35  | 0.580  | 
                  Why?
                 | 
| Levodopa | 6  | 2015  | 20  | 0.570  | 
                  Why?
                 | 
| Cellulose | 7  | 2017  | 21  | 0.570  | 
                  Why?
                 | 
| Zidovudine | 6  | 2017  | 59  | 0.570  | 
                  Why?
                 | 
| Mice | 11  | 2023  | 135  | 0.560  | 
                  Why?
                 | 
| Bioprinting | 5  | 2021  | 13  | 0.540  | 
                  Why?
                 | 
| Swine | 17  | 2019  | 49  | 0.540  | 
                  Why?
                 | 
| Gastric Mucosa | 3  | 2016  | 9  | 0.530  | 
                  Why?
                 | 
| Microscopy, Electron, Scanning | 11  | 2020  | 34  | 0.530  | 
                  Why?
                 | 
| Neurons | 6  | 2021  | 23  | 0.510  | 
                  Why?
                 | 
| Liposomes | 7  | 2022  | 33  | 0.510  | 
                  Why?
                 | 
| Metal Nanoparticles | 2  | 2017  | 26  | 0.510  | 
                  Why?
                 | 
| Nanotechnology | 6  | 2017  | 28  | 0.510  | 
                  Why?
                 | 
| Neuroprotective Agents | 3  | 2018  | 18  | 0.500  | 
                  Why?
                 | 
| Stomach | 2  | 2015  | 6  | 0.500  | 
                  Why?
                 | 
| Beer | 1  | 2015  | 3  | 0.490  | 
                  Why?
                 | 
| Nitrosamines | 1  | 2015  | 3  | 0.490  | 
                  Why?
                 | 
| Probiotics | 4  | 2016  | 12  | 0.490  | 
                  Why?
                 | 
| X-Ray Diffraction | 8  | 2021  | 14  | 0.490  | 
                  Why?
                 | 
| Esophageal Neoplasms | 1  | 2015  | 26  | 0.490  | 
                  Why?
                 | 
| Alzheimer Disease | 3  | 2018  | 30  | 0.480  | 
                  Why?
                 | 
| Biological Availability | 14  | 2021  | 43  | 0.480  | 
                  Why?
                 | 
| Carcinoma, Squamous Cell | 1  | 2015  | 32  | 0.480  | 
                  Why?
                 | 
| Technology, Pharmaceutical | 10  | 2022  | 35  | 0.470  | 
                  Why?
                 | 
| Neoplasms | 4  | 2023  | 147  | 0.470  | 
                  Why?
                 | 
| Drug Design | 7  | 2017  | 29  | 0.470  | 
                  Why?
                 | 
| Cross-Linking Reagents | 11  | 2021  | 33  | 0.470  | 
                  Why?
                 | 
| Calpain | 1  | 2014  | 2  | 0.470  | 
                  Why?
                 | 
| Polyphenols | 1  | 2014  | 3  | 0.470  | 
                  Why?
                 | 
| Adhesives | 2  | 2011  | 5  | 0.470  | 
                  Why?
                 | 
| Blood-Brain Barrier | 5  | 2019  | 24  | 0.460  | 
                  Why?
                 | 
| Wounds and Injuries | 1  | 2014  | 26  | 0.460  | 
                  Why?
                 | 
| Rats | 11  | 2023  | 130  | 0.450  | 
                  Why?
                 | 
| Polyesters | 5  | 2019  | 16  | 0.440  | 
                  Why?
                 | 
| Quercetin | 1  | 2014  | 3  | 0.440  | 
                  Why?
                 | 
| Polyvinyl Alcohol | 6  | 2016  | 16  | 0.440  | 
                  Why?
                 | 
| Inflammation | 6  | 2017  | 104  | 0.430  | 
                  Why?
                 | 
| Blood Platelets | 3  | 2021  | 30  | 0.430  | 
                  Why?
                 | 
| Polyelectrolytes | 3  | 2019  | 6  | 0.420  | 
                  Why?
                 | 
| Anti-Infective Agents | 2  | 2013  | 57  | 0.420  | 
                  Why?
                 | 
| Solubility | 14  | 2017  | 51  | 0.410  | 
                  Why?
                 | 
| Indomethacin | 6  | 2015  | 17  | 0.410  | 
                  Why?
                 | 
| Calcium Carbonate | 1  | 2013  | 3  | 0.410  | 
                  Why?
                 | 
| Computer Simulation | 10  | 2016  | 56  | 0.410  | 
                  Why?
                 | 
| Bandages, Hydrocolloid | 1  | 2012  | 1  | 0.410  | 
                  Why?
                 | 
| Cell Survival | 6  | 2020  | 48  | 0.400  | 
                  Why?
                 | 
| Sulpiride | 3  | 2019  | 7  | 0.400  | 
                  Why?
                 | 
| Porosity | 9  | 2018  | 24  | 0.390  | 
                  Why?
                 | 
| Patents as Topic | 6  | 2021  | 18  | 0.390  | 
                  Why?
                 | 
| Nanospheres | 3  | 2023  | 13  | 0.390  | 
                  Why?
                 | 
| Nerve Tissue | 3  | 2022  | 7  | 0.390  | 
                  Why?
                 | 
| Lipopolysaccharides | 3  | 2023  | 37  | 0.390  | 
                  Why?
                 | 
| Praziquantel | 2  | 2022  | 5  | 0.380  | 
                  Why?
                 | 
| Microspheres | 1  | 2011  | 8  | 0.380  | 
                  Why?
                 | 
| Cell Line | 4  | 2021  | 93  | 0.370  | 
                  Why?
                 | 
| Microinjections | 3  | 2017  | 9  | 0.370  | 
                  Why?
                 | 
| Durapatite | 1  | 2011  | 1  | 0.360  | 
                  Why?
                 | 
| HIV-1 | 3  | 2018  | 1260  | 0.360  | 
                  Why?
                 | 
| Diphenhydramine | 1  | 2011  | 2  | 0.360  | 
                  Why?
                 | 
| Anti-Allergic Agents | 1  | 2011  | 2  | 0.360  | 
                  Why?
                 | 
| Theranostic Nanomedicine | 3  | 2020  | 6  | 0.360  | 
                  Why?
                 | 
| Nicotine | 1  | 2011  | 12  | 0.350  | 
                  Why?
                 | 
| Surface Properties | 10  | 2020  | 46  | 0.350  | 
                  Why?
                 | 
| Cell Proliferation | 8  | 2020  | 45  | 0.350  | 
                  Why?
                 | 
| Gels | 4  | 2019  | 19  | 0.350  | 
                  Why?
                 | 
| Computational Biology | 1  | 2011  | 44  | 0.350  | 
                  Why?
                 | 
| Biomimetic Materials | 3  | 2020  | 7  | 0.340  | 
                  Why?
                 | 
| Polysaccharides | 4  | 2020  | 45  | 0.340  | 
                  Why?
                 | 
| Tuberculosis | 3  | 2023  | 543  | 0.340  | 
                  Why?
                 | 
| Administration, Cutaneous | 8  | 2018  | 31  | 0.340  | 
                  Why?
                 | 
| Ligands | 7  | 2018  | 33  | 0.320  | 
                  Why?
                 | 
| Brain | 6  | 2019  | 53  | 0.320  | 
                  Why?
                 | 
| Nanotubes, Carbon | 2  | 2020  | 9  | 0.310  | 
                  Why?
                 | 
| Polyglycolic Acid | 4  | 2014  | 16  | 0.310  | 
                  Why?
                 | 
| Lactic Acid | 4  | 2014  | 34  | 0.300  | 
                  Why?
                 | 
| Peripheral Nerve Injuries | 2  | 2021  | 4  | 0.300  | 
                  Why?
                 | 
| Needles | 4  | 2018  | 12  | 0.300  | 
                  Why?
                 | 
| Methacrylates | 4  | 2018  | 14  | 0.300  | 
                  Why?
                 | 
| Molecular Docking Simulation | 4  | 2016  | 38  | 0.300  | 
                  Why?
                 | 
| Diclofenac | 4  | 2016  | 10  | 0.290  | 
                  Why?
                 | 
| Cell Adhesion | 3  | 2012  | 18  | 0.290  | 
                  Why?
                 | 
| Stroke | 2  | 2019  | 62  | 0.290  | 
                  Why?
                 | 
| Excipients | 5  | 2015  | 13  | 0.280  | 
                  Why?
                 | 
| Lactobacillus acidophilus | 3  | 2016  | 6  | 0.280  | 
                  Why?
                 | 
| Intestinal Absorption | 4  | 2019  | 10  | 0.280  | 
                  Why?
                 | 
| Vagina | 5  | 2023  | 91  | 0.280  | 
                  Why?
                 | 
| Rats, Sprague-Dawley | 6  | 2021  | 63  | 0.270  | 
                  Why?
                 | 
| Antiviral Agents | 2  | 2018  | 111  | 0.270  | 
                  Why?
                 | 
| Nanocomposites | 2  | 2017  | 6  | 0.270  | 
                  Why?
                 | 
| Chemical Precipitation | 2  | 2017  | 4  | 0.270  | 
                  Why?
                 | 
| Cholecalciferol | 2  | 2017  | 8  | 0.260  | 
                  Why?
                 | 
| Arthritis | 2  | 2017  | 8  | 0.260  | 
                  Why?
                 | 
| Amyotrophic Lateral Sclerosis | 2  | 2018  | 14  | 0.260  | 
                  Why?
                 | 
| Extracellular Matrix | 3  | 2022  | 13  | 0.260  | 
                  Why?
                 | 
| Materials Testing | 4  | 2014  | 16  | 0.260  | 
                  Why?
                 | 
| Temperature | 8  | 2021  | 56  | 0.260  | 
                  Why?
                 | 
| Intestines | 3  | 2015  | 7  | 0.260  | 
                  Why?
                 | 
| Neurodegenerative Diseases | 2  | 2016  | 19  | 0.260  | 
                  Why?
                 | 
| Female | 17  | 2024  | 9103  | 0.250  | 
                  Why?
                 | 
| Calorimetry, Differential Scanning | 8  | 2018  | 20  | 0.250  | 
                  Why?
                 | 
| Drug Compounding | 3  | 2016  | 22  | 0.250  | 
                  Why?
                 | 
| Dopamine Agents | 3  | 2014  | 11  | 0.250  | 
                  Why?
                 | 
| Galantamine | 2  | 2018  | 6  | 0.250  | 
                  Why?
                 | 
| Skin | 5  | 2018  | 38  | 0.250  | 
                  Why?
                 | 
| Antiparkinson Agents | 2  | 2018  | 15  | 0.250  | 
                  Why?
                 | 
| Central Nervous System Agents | 2  | 2016  | 9  | 0.250  | 
                  Why?
                 | 
| Absorbable Implants | 2  | 2018  | 8  | 0.240  | 
                  Why?
                 | 
| Eye | 3  | 2014  | 13  | 0.240  | 
                  Why?
                 | 
| Interferon-beta | 2  | 2017  | 7  | 0.240  | 
                  Why?
                 | 
| Ciprofloxacin | 3  | 2013  | 11  | 0.240  | 
                  Why?
                 | 
| Tensile Strength | 5  | 2019  | 13  | 0.240  | 
                  Why?
                 | 
| Antipsychotic Agents | 2  | 2015  | 10  | 0.240  | 
                  Why?
                 | 
| Anti-Inflammatory Agents | 3  | 2013  | 39  | 0.240  | 
                  Why?
                 | 
| Mucins | 2  | 2016  | 5  | 0.230  | 
                  Why?
                 | 
| Kinetics | 8  | 2017  | 65  | 0.230  | 
                  Why?
                 | 
| Regeneration | 1  | 2025  | 3  | 0.230  | 
                  Why?
                 | 
| Stem Cells | 1  | 2025  | 4  | 0.230  | 
                  Why?
                 | 
| Thermodynamics | 6  | 2016  | 19  | 0.230  | 
                  Why?
                 | 
| Insulin | 2  | 2017  | 73  | 0.230  | 
                  Why?
                 | 
| Fibroblasts | 4  | 2023  | 14  | 0.230  | 
                  Why?
                 | 
| Nylons | 3  | 2014  | 7  | 0.230  | 
                  Why?
                 | 
| Rifampin | 4  | 2023  | 197  | 0.230  | 
                  Why?
                 | 
| Anti-Inflammatory Agents, Non-Steroidal | 2  | 2015  | 17  | 0.230  | 
                  Why?
                 | 
| Escherichia coli | 3  | 2013  | 30  | 0.220  | 
                  Why?
                 | 
| Copper | 4  | 2017  | 15  | 0.220  | 
                  Why?
                 | 
| Staphylococcus aureus | 3  | 2015  | 43  | 0.220  | 
                  Why?
                 | 
| Diarylquinolines | 1  | 2024  | 39  | 0.220  | 
                  Why?
                 | 
| Amyloid beta-Peptides | 3  | 2018  | 22  | 0.220  | 
                  Why?
                 | 
| Osteoarthritis | 1  | 2024  | 4  | 0.220  | 
                  Why?
                 | 
| Permeability | 7  | 2017  | 17  | 0.220  | 
                  Why?
                 | 
| Rabbits | 7  | 2023  | 35  | 0.220  | 
                  Why?
                 | 
| Lung | 1  | 2024  | 70  | 0.220  | 
                  Why?
                 | 
| Biosensing Techniques | 2  | 2014  | 6  | 0.220  | 
                  Why?
                 | 
| Administration, Buccal | 2  | 2015  | 7  | 0.210  | 
                  Why?
                 | 
| Chromatography, High Pressure Liquid | 3  | 2024  | 18  | 0.210  | 
                  Why?
                 | 
| Antitubercular Agents | 3  | 2024  | 322  | 0.210  | 
                  Why?
                 | 
| Administration, Intravaginal | 7  | 2023  | 50  | 0.210  | 
                  Why?
                 | 
| Chelating Agents | 3  | 2013  | 11  | 0.210  | 
                  Why?
                 | 
| Macromolecular Substances | 2  | 2021  | 5  | 0.210  | 
                  Why?
                 | 
| Cell Line, Tumor | 6  | 2020  | 71  | 0.210  | 
                  Why?
                 | 
| Estrogens | 1  | 2023  | 6  | 0.210  | 
                  Why?
                 | 
| Protein Kinase Inhibitors | 1  | 2023  | 11  | 0.200  | 
                  Why?
                 | 
| Menopause | 1  | 2023  | 24  | 0.200  | 
                  Why?
                 | 
| Polypharmacy | 1  | 2022  | 5  | 0.200  | 
                  Why?
                 | 
| Skin Absorption | 3  | 2017  | 8  | 0.200  | 
                  Why?
                 | 
| Arthritis, Rheumatoid | 1  | 2024  | 158  | 0.190  | 
                  Why?
                 | 
| Sciatic Nerve | 1  | 2021  | 2  | 0.190  | 
                  Why?
                 | 
| Vaccines | 1  | 2023  | 86  | 0.190  | 
                  Why?
                 | 
| Brain Ischemia | 2  | 2019  | 10  | 0.190  | 
                  Why?
                 | 
| Bone Regeneration | 2  | 2023  | 5  | 0.190  | 
                  Why?
                 | 
| Hydrophobic and Hydrophilic Interactions | 4  | 2015  | 10  | 0.180  | 
                  Why?
                 | 
| Isoniazid | 4  | 2023  | 110  | 0.180  | 
                  Why?
                 | 
| Models, Biological | 4  | 2015  | 77  | 0.180  | 
                  Why?
                 | 
| Schistosomiasis | 1  | 2021  | 8  | 0.180  | 
                  Why?
                 | 
| Anthelmintics | 1  | 2021  | 9  | 0.180  | 
                  Why?
                 | 
| Models, Theoretical | 3  | 2019  | 80  | 0.180  | 
                  Why?
                 | 
| Liver | 2  | 2018  | 74  | 0.170  | 
                  Why?
                 | 
| Naphthoquinones | 1  | 2020  | 3  | 0.170  | 
                  Why?
                 | 
| NIH 3T3 Cells | 3  | 2020  | 7  | 0.170  | 
                  Why?
                 | 
| Fluorescent Dyes | 2  | 2017  | 13  | 0.170  | 
                  Why?
                 | 
| Hexuronic Acids | 6  | 2017  | 19  | 0.170  | 
                  Why?
                 | 
| Glucuronic Acid | 6  | 2017  | 19  | 0.170  | 
                  Why?
                 | 
| Molecular Structure | 3  | 2014  | 32  | 0.170  | 
                  Why?
                 | 
| Freeze Drying | 4  | 2015  | 7  | 0.170  | 
                  Why?
                 | 
| Vitamins | 2  | 2017  | 23  | 0.170  | 
                  Why?
                 | 
| Calcium Compounds | 2  | 2019  | 4  | 0.170  | 
                  Why?
                 | 
| Silicates | 2  | 2019  | 4  | 0.170  | 
                  Why?
                 | 
| Hyaluronic Acid | 4  | 2024  | 9  | 0.170  | 
                  Why?
                 | 
| Prednisolone | 2  | 2017  | 10  | 0.170  | 
                  Why?
                 | 
| Amoxicillin | 2  | 2016  | 9  | 0.160  | 
                  Why?
                 | 
| Oleic Acid | 1  | 2019  | 2  | 0.160  | 
                  Why?
                 | 
| Magnesium | 1  | 2019  | 6  | 0.160  | 
                  Why?
                 | 
| Biomimetics | 1  | 2019  | 3  | 0.160  | 
                  Why?
                 | 
| Endostatins | 1  | 2019  | 2  | 0.160  | 
                  Why?
                 | 
| Rheology | 5  | 2021  | 13  | 0.160  | 
                  Why?
                 | 
| Electrochemical Techniques | 3  | 2013  | 9  | 0.160  | 
                  Why?
                 | 
| Folic Acid | 1  | 2019  | 12  | 0.160  | 
                  Why?
                 | 
| Models, Chemical | 3  | 2014  | 13  | 0.160  | 
                  Why?
                 | 
| PC12 Cells | 5  | 2019  | 16  | 0.160  | 
                  Why?
                 | 
| Image Processing, Computer-Assisted | 1  | 2019  | 9  | 0.160  | 
                  Why?
                 | 
| Adhesiveness | 6  | 2015  | 18  | 0.160  | 
                  Why?
                 | 
| Mycobacterium tuberculosis | 1  | 2023  | 329  | 0.160  | 
                  Why?
                 | 
| Root Canal Filling Materials | 1  | 2019  | 2  | 0.160  | 
                  Why?
                 | 
| Root Canal Irrigants | 1  | 2019  | 2  | 0.160  | 
                  Why?
                 | 
| Viscosity | 3  | 2015  | 16  | 0.160  | 
                  Why?
                 | 
| Lipids | 4  | 2022  | 81  | 0.160  | 
                  Why?
                 | 
| Ruthenium Compounds | 1  | 2019  | 3  | 0.160  | 
                  Why?
                 | 
| Dopamine Antagonists | 1  | 2019  | 3  | 0.160  | 
                  Why?
                 | 
| Dental Caries | 1  | 2019  | 10  | 0.160  | 
                  Why?
                 | 
| Glioblastoma | 1  | 2019  | 3  | 0.160  | 
                  Why?
                 | 
| Brain Neoplasms | 1  | 2019  | 6  | 0.160  | 
                  Why?
                 | 
| Ethylene Glycols | 2  | 2016  | 4  | 0.160  | 
                  Why?
                 | 
| Oligopeptides | 2  | 2023  | 16  | 0.160  | 
                  Why?
                 | 
| In Vitro Techniques | 3  | 2015  | 54  | 0.150  | 
                  Why?
                 | 
| Antineoplastic Protocols | 1  | 2018  | 4  | 0.150  | 
                  Why?
                 | 
| Ink | 1  | 2018  | 2  | 0.150  | 
                  Why?
                 | 
| Carcinoma | 1  | 2018  | 9  | 0.150  | 
                  Why?
                 | 
| Ovalbumin | 2  | 2016  | 5  | 0.150  | 
                  Why?
                 | 
| HIV Infections | 5  | 2024  | 5097  | 0.150  | 
                  Why?
                 | 
| Economics, Pharmaceutical | 1  | 2018  | 3  | 0.150  | 
                  Why?
                 | 
| Posterior Eye Segment | 1  | 2018  | 4  | 0.150  | 
                  Why?
                 | 
| Benzoxazines | 2  | 2018  | 123  | 0.150  | 
                  Why?
                 | 
| Dexamethasone | 1  | 2018  | 13  | 0.150  | 
                  Why?
                 | 
| Microbial Sensitivity Tests | 3  | 2016  | 198  | 0.150  | 
                  Why?
                 | 
| Acrylamide | 1  | 2018  | 2  | 0.150  | 
                  Why?
                 | 
| Biomechanical Phenomena | 1  | 2018  | 9  | 0.150  | 
                  Why?
                 | 
| Biomedical Technology | 1  | 2018  | 10  | 0.150  | 
                  Why?
                 | 
| Glycosaminoglycans | 1  | 2018  | 2  | 0.150  | 
                  Why?
                 | 
| Galactans | 2  | 2015  | 6  | 0.150  | 
                  Why?
                 | 
| Mannans | 2  | 2015  | 6  | 0.150  | 
                  Why?
                 | 
| Plant Gums | 2  | 2015  | 6  | 0.150  | 
                  Why?
                 | 
| Amides | 1  | 2018  | 8  | 0.150  | 
                  Why?
                 | 
| Apoproteins | 1  | 2018  | 2  | 0.150  | 
                  Why?
                 | 
| Lactoferrin | 1  | 2018  | 2  | 0.150  | 
                  Why?
                 | 
| Epichlorohydrin | 2  | 2016  | 4  | 0.150  | 
                  Why?
                 | 
| Calcitonin | 1  | 2018  | 10  | 0.150  | 
                  Why?
                 | 
| Antioxidants | 2  | 2018  | 26  | 0.150  | 
                  Why?
                 | 
| Pentetic Acid | 1  | 2018  | 4  | 0.140  | 
                  Why?
                 | 
| Amantadine | 1  | 2018  | 6  | 0.140  | 
                  Why?
                 | 
| Iron | 1  | 2018  | 32  | 0.140  | 
                  Why?
                 | 
| Sewage | 1  | 2017  | 2  | 0.140  | 
                  Why?
                 | 
| Metals | 1  | 2017  | 6  | 0.140  | 
                  Why?
                 | 
| Molecular Imaging | 1  | 2017  | 3  | 0.140  | 
                  Why?
                 | 
| Elastic Modulus | 5  | 2018  | 12  | 0.140  | 
                  Why?
                 | 
| alpha-Tocopherol | 1  | 2017  | 2  | 0.140  | 
                  Why?
                 | 
| Cyclodextrins | 1  | 2017  | 3  | 0.140  | 
                  Why?
                 | 
| Aminosalicylic Acid | 1  | 2017  | 2  | 0.140  | 
                  Why?
                 | 
| Ascorbic Acid | 1  | 2017  | 13  | 0.140  | 
                  Why?
                 | 
| Acyclovir | 1  | 2017  | 11  | 0.140  | 
                  Why?
                 | 
| Hepatitis B, Chronic | 1  | 2018  | 45  | 0.140  | 
                  Why?
                 | 
| Quaternary Ammonium Compounds | 1  | 2017  | 2  | 0.140  | 
                  Why?
                 | 
| Humic Substances | 1  | 2017  | 2  | 0.140  | 
                  Why?
                 | 
| Diagnostic Imaging | 2  | 2014  | 9  | 0.140  | 
                  Why?
                 | 
| Tissue Adhesives | 2  | 2014  | 5  | 0.140  | 
                  Why?
                 | 
| Amino Acid Sequence | 2  | 2014  | 139  | 0.140  | 
                  Why?
                 | 
| Erythropoietin | 1  | 2017  | 8  | 0.140  | 
                  Why?
                 | 
| Analgesia | 1  | 2017  | 8  | 0.130  | 
                  Why?
                 | 
| Parkinson Disease | 2  | 2016  | 19  | 0.130  | 
                  Why?
                 | 
| Fractures, Bone | 1  | 2017  | 21  | 0.130  | 
                  Why?
                 | 
| Molecular Sequence Data | 2  | 2014  | 263  | 0.130  | 
                  Why?
                 | 
| Gelatin | 1  | 2016  | 2  | 0.130  | 
                  Why?
                 | 
| Flavonoids | 2  | 2016  | 7  | 0.130  | 
                  Why?
                 | 
| Colon | 2  | 2015  | 8  | 0.130  | 
                  Why?
                 | 
| Chondroitin Sulfate Proteoglycans | 1  | 2016  | 2  | 0.130  | 
                  Why?
                 | 
| Eye Diseases | 1  | 2016  | 7  | 0.130  | 
                  Why?
                 | 
| Adenocarcinoma | 1  | 2016  | 10  | 0.130  | 
                  Why?
                 | 
| Felodipine | 1  | 2016  | 2  | 0.130  | 
                  Why?
                 | 
| Calcium Phosphates | 1  | 2016  | 3  | 0.130  | 
                  Why?
                 | 
| Drug Implants | 1  | 2016  | 24  | 0.130  | 
                  Why?
                 | 
| Central Nervous System Diseases | 1  | 2016  | 7  | 0.130  | 
                  Why?
                 | 
| Molecular Conformation | 2  | 2013  | 14  | 0.130  | 
                  Why?
                 | 
| Molecular Weight | 2  | 2013  | 13  | 0.130  | 
                  Why?
                 | 
| Carmustine | 1  | 2016  | 3  | 0.130  | 
                  Why?
                 | 
| Antineoplastic Agents, Alkylating | 1  | 2016  | 4  | 0.130  | 
                  Why?
                 | 
| Computer-Aided Design | 1  | 2016  | 6  | 0.130  | 
                  Why?
                 | 
| Industry | 1  | 2016  | 6  | 0.130  | 
                  Why?
                 | 
| Magnetite Nanoparticles | 1  | 2016  | 4  | 0.130  | 
                  Why?
                 | 
| Hepatitis B virus | 1  | 2018  | 157  | 0.130  | 
                  Why?
                 | 
| Mental Disorders | 1  | 2016  | 44  | 0.120  | 
                  Why?
                 | 
| Membranes | 1  | 2015  | 3  | 0.120  | 
                  Why?
                 | 
| Ganciclovir | 1  | 2015  | 12  | 0.120  | 
                  Why?
                 | 
| N-Nitrosopyrrolidine | 1  | 2015  | 3  | 0.120  | 
                  Why?
                 | 
| S100 Proteins | 1  | 2015  | 4  | 0.120  | 
                  Why?
                 | 
| Schizophrenia | 1  | 2015  | 4  | 0.120  | 
                  Why?
                 | 
| Chemotactic Factors | 1  | 2015  | 6  | 0.120  | 
                  Why?
                 | 
| Carcinogens | 1  | 2015  | 6  | 0.120  | 
                  Why?
                 | 
| Aminocaproic Acid | 1  | 2015  | 2  | 0.120  | 
                  Why?
                 | 
| Lipase | 1  | 2015  | 3  | 0.120  | 
                  Why?
                 | 
| Bile Acids and Salts | 1  | 2015  | 3  | 0.120  | 
                  Why?
                 | 
| Drug Resistance | 1  | 2015  | 35  | 0.120  | 
                  Why?
                 | 
| AIDS Dementia Complex | 1  | 2015  | 29  | 0.120  | 
                  Why?
                 | 
| Microwaves | 1  | 2015  | 3  | 0.120  | 
                  Why?
                 | 
| Dosage Forms | 2  | 2015  | 8  | 0.120  | 
                  Why?
                 | 
| Polystyrenes | 2  | 2015  | 4  | 0.120  | 
                  Why?
                 | 
| Hot Temperature | 4  | 2018  | 28  | 0.120  | 
                  Why?
                 | 
| Polyphosphates | 4  | 2019  | 10  | 0.120  | 
                  Why?
                 | 
| Phenytoin | 1  | 2015  | 4  | 0.120  | 
                  Why?
                 | 
| Mouth Mucosa | 1  | 2015  | 7  | 0.120  | 
                  Why?
                 | 
| Menthol | 1  | 2014  | 2  | 0.120  | 
                  Why?
                 | 
| Sulfamethoxazole | 1  | 2014  | 2  | 0.120  | 
                  Why?
                 | 
| Cysteine Proteinase Inhibitors | 1  | 2014  | 2  | 0.120  | 
                  Why?
                 | 
| Molecular Dynamics Simulation | 1  | 2014  | 25  | 0.120  | 
                  Why?
                 | 
| Skin Physiological Phenomena | 1  | 2014  | 5  | 0.110  | 
                  Why?
                 | 
| Timolol | 1  | 2014  | 3  | 0.110  | 
                  Why?
                 | 
| Ophthalmic Solutions | 1  | 2014  | 9  | 0.110  | 
                  Why?
                 | 
| Phenol | 1  | 2014  | 4  | 0.110  | 
                  Why?
                 | 
| Oxidation-Reduction | 3  | 2020  | 24  | 0.110  | 
                  Why?
                 | 
| Steroids | 1  | 2014  | 14  | 0.110  | 
                  Why?
                 | 
| Reactive Oxygen Species | 1  | 2014  | 23  | 0.110  | 
                  Why?
                 | 
| Analgesia, Patient-Controlled | 1  | 2013  | 3  | 0.110  | 
                  Why?
                 | 
| Analgesics | 1  | 2013  | 4  | 0.110  | 
                  Why?
                 | 
| Pain Management | 1  | 2013  | 12  | 0.110  | 
                  Why?
                 | 
| Glutathione Transferase | 1  | 2014  | 20  | 0.110  | 
                  Why?
                 | 
| Periodontal Diseases | 1  | 2013  | 2  | 0.110  | 
                  Why?
                 | 
| Antihypertensive Agents | 1  | 2014  | 64  | 0.110  | 
                  Why?
                 | 
| Eye, Artificial | 1  | 2013  | 3  | 0.110  | 
                  Why?
                 | 
| Carbohydrates | 1  | 2013  | 5  | 0.110  | 
                  Why?
                 | 
| Anterior Eye Segment | 1  | 2013  | 3  | 0.110  | 
                  Why?
                 | 
| Multiple Sclerosis | 1  | 2013  | 4  | 0.110  | 
                  Why?
                 | 
| Drug Chronotherapy | 1  | 2013  | 5  | 0.110  | 
                  Why?
                 | 
| Metabolic Networks and Pathways | 1  | 2013  | 2  | 0.110  | 
                  Why?
                 | 
| Iridoids | 3  | 2021  | 7  | 0.110  | 
                  Why?
                 | 
| Mucous Membrane | 1  | 2013  | 12  | 0.110  | 
                  Why?
                 | 
| Ergocalciferols | 1  | 2013  | 3  | 0.110  | 
                  Why?
                 | 
| Edetic Acid | 1  | 2013  | 8  | 0.110  | 
                  Why?
                 | 
| Dental Materials | 1  | 2013  | 2  | 0.100  | 
                  Why?
                 | 
| Nootropic Agents | 1  | 2013  | 4  | 0.100  | 
                  Why?
                 | 
| Software | 1  | 2013  | 37  | 0.100  | 
                  Why?
                 | 
| Diabetes Mellitus, Experimental | 1  | 2013  | 6  | 0.100  | 
                  Why?
                 | 
| Practice Patterns, Physicians' | 1  | 2013  | 43  | 0.100  | 
                  Why?
                 | 
| Mesalamine | 1  | 2012  | 2  | 0.100  | 
                  Why?
                 | 
| Hypoglycemic Agents | 1  | 2013  | 10  | 0.100  | 
                  Why?
                 | 
| Cytochrome P-450 CYP3A Inhibitors | 1  | 2012  | 3  | 0.100  | 
                  Why?
                 | 
| Potassium Compounds | 1  | 2012  | 4  | 0.100  | 
                  Why?
                 | 
| Polymerization | 1  | 2012  | 4  | 0.100  | 
                  Why?
                 | 
| Sulfates | 1  | 2012  | 7  | 0.100  | 
                  Why?
                 | 
| Enzyme Inhibitors | 1  | 2012  | 22  | 0.100  | 
                  Why?
                 | 
| Caco-2 Cells | 3  | 2019  | 10  | 0.100  | 
                  Why?
                 | 
| Blood Coagulation | 1  | 2012  | 29  | 0.100  | 
                  Why?
                 | 
| Polyethyleneimine | 3  | 2019  | 8  | 0.100  | 
                  Why?
                 | 
| Drug Stability | 3  | 2017  | 13  | 0.100  | 
                  Why?
                 | 
| Equipment Design | 3  | 2018  | 27  | 0.100  | 
                  Why?
                 | 
| Metformin | 1  | 2011  | 3  | 0.090  | 
                  Why?
                 | 
| Intestinal Mucosa | 3  | 2016  | 9  | 0.090  | 
                  Why?
                 | 
| Disease Models, Animal | 2  | 2022  | 45  | 0.090  | 
                  Why?
                 | 
| Organic Chemistry Phenomena | 1  | 2011  | 2  | 0.090  | 
                  Why?
                 | 
| Diabetes Mellitus | 1  | 2013  | 146  | 0.090  | 
                  Why?
                 | 
| Vero Cells | 1  | 2011  | 6  | 0.090  | 
                  Why?
                 | 
| Light | 2  | 2021  | 12  | 0.090  | 
                  Why?
                 | 
| Powders | 3  | 2017  | 7  | 0.090  | 
                  Why?
                 | 
| Peptidomimetics | 1  | 2011  | 4  | 0.090  | 
                  Why?
                 | 
| Prostheses and Implants | 1  | 2011  | 5  | 0.090  | 
                  Why?
                 | 
| Protein Structure, Secondary | 1  | 2011  | 12  | 0.090  | 
                  Why?
                 | 
| Axons | 2  | 2021  | 7  | 0.090  | 
                  Why?
                 | 
| Microscopy, Electron, Transmission | 3  | 2018  | 18  | 0.090  | 
                  Why?
                 | 
| Spectrophotometry, Ultraviolet | 2  | 2024  | 8  | 0.080  | 
                  Why?
                 | 
| Tenofovir | 2  | 2024  | 171  | 0.080  | 
                  Why?
                 | 
| Capsules | 2  | 2023  | 4  | 0.080  | 
                  Why?
                 | 
| Cardiovascular Diseases | 1  | 2013  | 237  | 0.080  | 
                  Why?
                 | 
| Blood Glucose | 3  | 2017  | 107  | 0.080  | 
                  Why?
                 | 
| Mice, Nude | 2  | 2019  | 12  | 0.080  | 
                  Why?
                 | 
| Injections | 2  | 2021  | 31  | 0.080  | 
                  Why?
                 | 
| Poloxamer | 2  | 2019  | 9  | 0.070  | 
                  Why?
                 | 
| Male | 5  | 2021  | 6754  | 0.070  | 
                  Why?
                 | 
| Administration, Intranasal | 2  | 2019  | 8  | 0.070  | 
                  Why?
                 | 
| Endocytosis | 2  | 2019  | 6  | 0.070  | 
                  Why?
                 | 
| Biological Transport | 2  | 2019  | 11  | 0.070  | 
                  Why?
                 | 
| Cells, Cultured | 2  | 2018  | 79  | 0.070  | 
                  Why?
                 | 
| Water | 2  | 2019  | 22  | 0.070  | 
                  Why?
                 | 
| Thermogravimetry | 2  | 2018  | 4  | 0.070  | 
                  Why?
                 | 
| Hypromellose Derivatives | 2  | 2019  | 5  | 0.070  | 
                  Why?
                 | 
| Alkynes | 2  | 2018  | 117  | 0.060  | 
                  Why?
                 | 
| Cyclopropanes | 2  | 2018  | 123  | 0.060  | 
                  Why?
                 | 
| Fluorescein-5-isothiocyanate | 2  | 2016  | 7  | 0.060  | 
                  Why?
                 | 
| Calcium Chloride | 2  | 2019  | 4  | 0.060  | 
                  Why?
                 | 
| Stress, Mechanical | 2  | 2018  | 16  | 0.060  | 
                  Why?
                 | 
| Phospholipids | 2  | 2017  | 13  | 0.060  | 
                  Why?
                 | 
| Electric Stimulation | 2  | 2017  | 7  | 0.060  | 
                  Why?
                 | 
| Spectrum Analysis | 2  | 2018  | 8  | 0.060  | 
                  Why?
                 | 
| Sus scrofa | 2  | 2016  | 4  | 0.060  | 
                  Why?
                 | 
| Magnetic Resonance Imaging | 2  | 2018  | 37  | 0.060  | 
                  Why?
                 | 
| Stem Cell Transplantation | 1  | 2025  | 5  | 0.060  | 
                  Why?
                 | 
| Chromatography, Reverse-Phase | 1  | 2024  | 2  | 0.060  | 
                  Why?
                 | 
| Administration, Topical | 2  | 2015  | 12  | 0.060  | 
                  Why?
                 | 
| Limit of Detection | 1  | 2024  | 14  | 0.060  | 
                  Why?
                 | 
| Microsomes, Liver | 2  | 2016  | 9  | 0.060  | 
                  Why?
                 | 
| Cytochrome P-450 CYP3A | 2  | 2016  | 11  | 0.060  | 
                  Why?
                 | 
| Zinc | 2  | 2016  | 10  | 0.060  | 
                  Why?
                 | 
| Magnetic Resonance Spectroscopy | 2  | 2015  | 5  | 0.060  | 
                  Why?
                 | 
| Aerosols | 1  | 2024  | 7  | 0.060  | 
                  Why?
                 | 
| Administration, Inhalation | 1  | 2024  | 5  | 0.060  | 
                  Why?
                 | 
| Emulsions | 2  | 2016  | 5  | 0.050  | 
                  Why?
                 | 
| Reproducibility of Results | 1  | 2024  | 217  | 0.050  | 
                  Why?
                 | 
| Genitalia, Female | 1  | 2024  | 17  | 0.050  | 
                  Why?
                 | 
| Antigen Presentation | 1  | 2023  | 6  | 0.050  | 
                  Why?
                 | 
| Antigens | 1  | 2023  | 11  | 0.050  | 
                  Why?
                 | 
| Osteogenesis | 1  | 2023  | 3  | 0.050  | 
                  Why?
                 | 
| Bone Morphogenetic Protein 7 | 1  | 2023  | 3  | 0.050  | 
                  Why?
                 | 
| Immunologic Factors | 1  | 2023  | 9  | 0.050  | 
                  Why?
                 | 
| Estradiol | 1  | 2023  | 18  | 0.050  | 
                  Why?
                 | 
| Carboxymethylcellulose Sodium | 2  | 2013  | 10  | 0.050  | 
                  Why?
                 | 
| Adjuvants, Immunologic | 1  | 2023  | 23  | 0.050  | 
                  Why?
                 | 
| Mannose | 1  | 2023  | 5  | 0.050  | 
                  Why?
                 | 
| Macrophages | 1  | 2023  | 15  | 0.050  | 
                  Why?
                 | 
| Precision Medicine | 1  | 2022  | 10  | 0.050  | 
                  Why?
                 | 
| South Africa | 1  | 2015  | 7596  | 0.050  | 
                  Why?
                 | 
| Algorithms | 2  | 2014  | 106  | 0.050  | 
                  Why?
                 | 
| Guided Tissue Regeneration | 1  | 2021  | 2  | 0.050  | 
                  Why?
                 | 
| Cues | 1  | 2021  | 3  | 0.050  | 
                  Why?
                 | 
| Prolamins | 1  | 2021  | 3  | 0.050  | 
                  Why?
                 | 
| Azo Compounds | 1  | 2021  | 6  | 0.050  | 
                  Why?
                 | 
| Phototherapy | 1  | 2021  | 6  | 0.050  | 
                  Why?
                 | 
| Proton Magnetic Resonance Spectroscopy | 1  | 2020  | 2  | 0.040  | 
                  Why?
                 | 
| Spectrometry, Fluorescence | 1  | 2020  | 6  | 0.040  | 
                  Why?
                 | 
| Cell Shape | 1  | 2020  | 3  | 0.040  | 
                  Why?
                 | 
| Inhibitory Concentration 50 | 1  | 2020  | 19  | 0.040  | 
                  Why?
                 | 
| Electrodes | 1  | 2020  | 7  | 0.040  | 
                  Why?
                 | 
| Carbohydrate Conformation | 1  | 2020  | 2  | 0.040  | 
                  Why?
                 | 
| Biomedical Engineering | 1  | 2020  | 2  | 0.040  | 
                  Why?
                 | 
| Mechanical Phenomena | 1  | 2020  | 2  | 0.040  | 
                  Why?
                 | 
| Chemical Phenomena | 1  | 2020  | 6  | 0.040  | 
                  Why?
                 | 
| Acetylcysteine | 1  | 2019  | 4  | 0.040  | 
                  Why?
                 | 
| Tumor Burden | 1  | 2019  | 2  | 0.040  | 
                  Why?
                 | 
| Xenograft Model Antitumor Assays | 1  | 2019  | 3  | 0.040  | 
                  Why?
                 | 
| Necrosis | 1  | 2019  | 7  | 0.040  | 
                  Why?
                 | 
| Mice, Inbred BALB C | 1  | 2019  | 11  | 0.040  | 
                  Why?
                 | 
| Medication Adherence | 1  | 2021  | 151  | 0.040  | 
                  Why?
                 | 
| Cell Movement | 1  | 2019  | 13  | 0.040  | 
                  Why?
                 | 
| Aged | 2  | 2016  | 1740  | 0.040  | 
                  Why?
                 | 
| Calcium Hydroxide | 1  | 2019  | 2  | 0.040  | 
                  Why?
                 | 
| Glass | 1  | 2019  | 2  | 0.040  | 
                  Why?
                 | 
| Gutta-Percha | 1  | 2019  | 2  | 0.040  | 
                  Why?
                 | 
| Root Canal Therapy | 1  | 2019  | 2  | 0.040  | 
                  Why?
                 | 
| Immunoglobulin G | 1  | 2021  | 231  | 0.040  | 
                  Why?
                 | 
| Propanolamines | 1  | 2019  | 8  | 0.040  | 
                  Why?
                 | 
| Drug Screening Assays, Antitumor | 1  | 2019  | 10  | 0.040  | 
                  Why?
                 | 
| Tumor Cells, Cultured | 1  | 2019  | 20  | 0.040  | 
                  Why?
                 | 
| Body Weight | 1  | 2019  | 111  | 0.040  | 
                  Why?
                 | 
| Acrylamides | 1  | 2018  | 3  | 0.040  | 
                  Why?
                 | 
| Povidone | 1  | 2018  | 3  | 0.040  | 
                  Why?
                 | 
| Micelles | 1  | 2018  | 6  | 0.040  | 
                  Why?
                 | 
| Methotrexate | 1  | 2018  | 17  | 0.040  | 
                  Why?
                 | 
| Intravitreal Injections | 1  | 2018  | 2  | 0.040  | 
                  Why?
                 | 
| Catalysis | 1  | 2018  | 6  | 0.040  | 
                  Why?
                 | 
| Green Chemistry Technology | 1  | 2018  | 2  | 0.040  | 
                  Why?
                 | 
| Hepatocytes | 1  | 2018  | 19  | 0.040  | 
                  Why?
                 | 
| Glycoconjugates | 1  | 2018  | 2  | 0.040  | 
                  Why?
                 | 
| Protein Conformation, beta-Strand | 1  | 2018  | 3  | 0.040  | 
                  Why?
                 | 
| Protein Conformation, alpha-Helical | 1  | 2018  | 4  | 0.040  | 
                  Why?
                 | 
| Hepatitis B Surface Antigens | 1  | 2018  | 48  | 0.040  | 
                  Why?
                 | 
| Iron Chelating Agents | 1  | 2018  | 7  | 0.040  | 
                  Why?
                 | 
| tau Proteins | 1  | 2018  | 7  | 0.040  | 
                  Why?
                 | 
| Protein Interaction Domains and Motifs | 1  | 2018  | 13  | 0.040  | 
                  Why?
                 | 
| Injections, Intramuscular | 1  | 2018  | 31  | 0.040  | 
                  Why?
                 | 
| Pregnancy | 1  | 2024  | 1862  | 0.040  | 
                  Why?
                 | 
| Binding Sites | 1  | 2018  | 43  | 0.040  | 
                  Why?
                 | 
| Glycine | 1  | 2017  | 2  | 0.040  | 
                  Why?
                 | 
| Protein Binding | 1  | 2018  | 62  | 0.040  | 
                  Why?
                 | 
| Fluorescence Resonance Energy Transfer | 1  | 2017  | 2  | 0.040  | 
                  Why?
                 | 
| Molecular Probes | 1  | 2017  | 4  | 0.040  | 
                  Why?
                 | 
| Emtricitabine | 1  | 2018  | 78  | 0.040  | 
                  Why?
                 | 
| Bone and Bones | 1  | 2018  | 38  | 0.040  | 
                  Why?
                 | 
| Viscosupplementation | 1  | 2017  | 2  | 0.040  | 
                  Why?
                 | 
| Nuclear Magnetic Resonance, Biomolecular | 1  | 2017  | 3  | 0.040  | 
                  Why?
                 | 
| Carbon Isotopes | 1  | 2017  | 5  | 0.040  | 
                  Why?
                 | 
| Young Adult | 2  | 2016  | 2498  | 0.040  | 
                  Why?
                 | 
| 2-Hydroxypropyl-beta-cyclodextrin | 1  | 2017  | 2  | 0.040  | 
                  Why?
                 | 
| Disease Management | 1  | 2018  | 74  | 0.030  | 
                  Why?
                 | 
| Intestine, Small | 1  | 2017  | 4  | 0.030  | 
                  Why?
                 | 
| Tumor Microenvironment | 1  | 2017  | 9  | 0.030  | 
                  Why?
                 | 
| Surface-Active Agents | 1  | 2017  | 4  | 0.030  | 
                  Why?
                 | 
| Gastric Absorption | 1  | 2017  | 3  | 0.030  | 
                  Why?
                 | 
| Clavicle | 1  | 2017  | 2  | 0.030  | 
                  Why?
                 | 
| Polypropylenes | 1  | 2017  | 2  | 0.030  | 
                  Why?
                 | 
| Fracture Healing | 1  | 2017  | 2  | 0.030  | 
                  Why?
                 | 
| Simvastatin | 1  | 2017  | 10  | 0.030  | 
                  Why?
                 | 
| Serum Albumin, Bovine | 1  | 2016  | 2  | 0.030  | 
                  Why?
                 | 
| RNA, Viral | 1  | 2018  | 303  | 0.030  | 
                  Why?
                 | 
| Microbial Viability | 1  | 2016  | 11  | 0.030  | 
                  Why?
                 | 
| Magnetic Fields | 1  | 2016  | 2  | 0.030  | 
                  Why?
                 | 
| Biopolymers | 1  | 2016  | 4  | 0.030  | 
                  Why?
                 | 
| Neovascularization, Pathologic | 1  | 2016  | 4  | 0.030  | 
                  Why?
                 | 
| Cost-Benefit Analysis | 1  | 2018  | 253  | 0.030  | 
                  Why?
                 | 
| Acrylates | 1  | 2016  | 2  | 0.030  | 
                  Why?
                 | 
| Crystallization | 1  | 2016  | 8  | 0.030  | 
                  Why?
                 | 
| Central Nervous System | 1  | 2016  | 11  | 0.030  | 
                  Why?
                 | 
| Middle Aged | 2  | 2016  | 3601  | 0.030  | 
                  Why?
                 | 
| Tissue Distribution | 1  | 2016  | 10  | 0.030  | 
                  Why?
                 | 
| Flavanones | 1  | 2016  | 4  | 0.030  | 
                  Why?
                 | 
| Silver | 1  | 2016  | 15  | 0.030  | 
                  Why?
                 | 
| Research | 1  | 2016  | 65  | 0.030  | 
                  Why?
                 | 
| Equipment and Supplies | 1  | 2016  | 3  | 0.030  | 
                  Why?
                 | 
| Drug Industry | 1  | 2016  | 5  | 0.030  | 
                  Why?
                 | 
| Pyrrolidonecarboxylic Acid | 1  | 2015  | 2  | 0.030  | 
                  Why?
                 | 
| Ultrasonic Waves | 1  | 2015  | 2  | 0.030  | 
                  Why?
                 | 
| Malonates | 1  | 2015  | 2  | 0.030  | 
                  Why?
                 | 
| Vitamin D | 1  | 2015  | 41  | 0.030  | 
                  Why?
                 | 
| Lactose | 1  | 2015  | 2  | 0.030  | 
                  Why?
                 | 
| Tablets, Enteric-Coated | 1  | 2015  | 2  | 0.030  | 
                  Why?
                 | 
| Capillary Permeability | 1  | 2015  | 4  | 0.030  | 
                  Why?
                 | 
| Polymethyl Methacrylate | 1  | 2014  | 2  | 0.030  | 
                  Why?
                 | 
| Drug Evaluation, Preclinical | 1  | 2014  | 11  | 0.030  | 
                  Why?
                 | 
| Cell Engineering | 1  | 2014  | 2  | 0.030  | 
                  Why?
                 | 
| Nerve Growth Factors | 1  | 2014  | 5  | 0.030  | 
                  Why?
                 | 
| Hardness Tests | 1  | 2014  | 2  | 0.030  | 
                  Why?
                 | 
| Cell- and Tissue-Based Therapy | 1  | 2014  | 5  | 0.030  | 
                  Why?
                 | 
| Chorioallantoic Membrane | 1  | 2014  | 3  | 0.030  | 
                  Why?
                 | 
| Administration, Ophthalmic | 1  | 2014  | 3  | 0.030  | 
                  Why?
                 | 
| Chick Embryo | 1  | 2014  | 8  | 0.030  | 
                  Why?
                 | 
| Infusion Pumps | 1  | 2013  | 3  | 0.030  | 
                  Why?
                 | 
| Iontophoresis | 1  | 2013  | 5  | 0.030  | 
                  Why?
                 | 
| Plasticizers | 1  | 2013  | 4  | 0.030  | 
                  Why?
                 | 
| Enterococcus faecalis | 1  | 2013  | 2  | 0.030  | 
                  Why?
                 | 
| Imidazoles | 1  | 2013  | 9  | 0.030  | 
                  Why?
                 | 
| Streptococcus mutans | 1  | 2013  | 6  | 0.030  | 
                  Why?
                 | 
| Amitriptyline | 1  | 2013  | 3  | 0.030  | 
                  Why?
                 | 
| Antidepressive Agents, Tricyclic | 1  | 2013  | 3  | 0.030  | 
                  Why?
                 | 
| Electrolytes | 1  | 2013  | 5  | 0.030  | 
                  Why?
                 | 
| Theophylline | 1  | 2013  | 5  | 0.030  | 
                  Why?
                 | 
| Diltiazem | 1  | 2013  | 2  | 0.030  | 
                  Why?
                 | 
| Methylcellulose | 1  | 2013  | 2  | 0.030  | 
                  Why?
                 | 
| Phosphodiesterase Inhibitors | 1  | 2013  | 10  | 0.030  | 
                  Why?
                 | 
| Endocrine System | 1  | 2013  | 3  | 0.030  | 
                  Why?
                 | 
| Electric Conductivity | 1  | 2013  | 4  | 0.030  | 
                  Why?
                 | 
| Metabolomics | 1  | 2013  | 5  | 0.030  | 
                  Why?
                 | 
| Feedback | 1  | 2013  | 6  | 0.030  | 
                  Why?
                 | 
| Drug Synergism | 1  | 2013  | 20  | 0.030  | 
                  Why?
                 | 
| Adult | 2  | 2016  | 5913  | 0.030  | 
                  Why?
                 | 
| NF-kappa B | 1  | 2013  | 16  | 0.030  | 
                  Why?
                 | 
| Hardness | 1  | 2013  | 7  | 0.030  | 
                  Why?
                 | 
| Models, Statistical | 1  | 2013  | 55  | 0.030  | 
                  Why?
                 | 
| Structure-Activity Relationship | 1  | 2013  | 28  | 0.030  | 
                  Why?
                 | 
| Dose-Response Relationship, Drug | 1  | 2013  | 125  | 0.030  | 
                  Why?
                 | 
| Cholesterol | 1  | 2013  | 38  | 0.030  | 
                  Why?
                 | 
| Solvents | 1  | 2013  | 15  | 0.030  | 
                  Why?
                 | 
| Chromatography, Gel | 1  | 2013  | 4  | 0.030  | 
                  Why?
                 | 
| Hydrochloric Acid | 1  | 2013  | 4  | 0.030  | 
                  Why?
                 | 
| Barium Sulfate | 1  | 2012  | 2  | 0.030  | 
                  Why?
                 | 
| beta-Glucosidase | 1  | 2012  | 2  | 0.030  | 
                  Why?
                 | 
| Polygalacturonase | 1  | 2012  | 2  | 0.030  | 
                  Why?
                 | 
| Life Style | 1  | 2013  | 86  | 0.030  | 
                  Why?
                 | 
| Early Diagnosis | 1  | 2013  | 82  | 0.030  | 
                  Why?
                 | 
| Health Behavior | 1  | 2013  | 79  | 0.020  | 
                  Why?
                 | 
| Chronic Disease | 1  | 2013  | 107  | 0.020  | 
                  Why?
                 | 
| Glutaral | 1  | 2012  | 2  | 0.020  | 
                  Why?
                 | 
| Oligosaccharides | 1  | 2012  | 2  | 0.020  | 
                  Why?
                 | 
| Cations | 1  | 2012  | 7  | 0.020  | 
                  Why?
                 | 
| Biomarkers | 1  | 2013  | 327  | 0.020  | 
                  Why?
                 | 
| Lecithins | 1  | 2011  | 4  | 0.020  | 
                  Why?
                 | 
| Hexoses | 1  | 2011  | 2  | 0.020  | 
                  Why?
                 | 
| Glycoproteins | 1  | 2011  | 10  | 0.020  | 
                  Why?
                 | 
| Antigens, Surface | 1  | 2011  | 11  | 0.020  | 
                  Why?
                 |